Matches in Wikidata for { <http://www.wikidata.org/entity/Q98228738> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- Q98228738 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q98228738 description "scientific article published on 17 June 2020" @default.
- Q98228738 description "wetenschappelijk artikel" @default.
- Q98228738 description "наукова стаття, опублікована 17 червня 2020" @default.
- Q98228738 description "գիտական հոդված հրատարակված 2020 թվականի հունիսի 17-ին" @default.
- Q98228738 name "Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab" @default.
- Q98228738 name "Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab" @default.
- Q98228738 type Item @default.
- Q98228738 label "Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab" @default.
- Q98228738 label "Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab" @default.
- Q98228738 prefLabel "Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab" @default.
- Q98228738 prefLabel "Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab" @default.
- Q98228738 P1433 Q98228738-15F46CD0-B636-472F-9864-112D4F443262 @default.
- Q98228738 P1476 Q98228738-1D35FB07-28B5-4F78-960E-1180F5BD0F4D @default.
- Q98228738 P2093 Q98228738-13D4B3A1-B902-4A1F-ADE5-898149AD0169 @default.
- Q98228738 P2093 Q98228738-21B66CFD-D908-49E9-BD5B-D509B17E36FB @default.
- Q98228738 P2093 Q98228738-2C5839D6-6AE1-4563-8C14-AC515311A8A1 @default.
- Q98228738 P2093 Q98228738-3EDF2288-5FBA-4161-BCE2-103E9E2F4737 @default.
- Q98228738 P2093 Q98228738-68BF6A5F-426B-4549-B158-E1A7F6257D25 @default.
- Q98228738 P2093 Q98228738-6E40BD82-1157-4096-B0AB-7CAD5F023E6D @default.
- Q98228738 P2093 Q98228738-722243CF-2DB9-4FDB-9EC8-A9A4BF02DF55 @default.
- Q98228738 P2093 Q98228738-7814B76E-D7DB-4020-861B-4CFAADD0CBBA @default.
- Q98228738 P2093 Q98228738-791C1617-D881-4F2A-AD4B-228BED295006 @default.
- Q98228738 P2093 Q98228738-8A1241EF-E9C4-4DA0-949D-9E3D96084820 @default.
- Q98228738 P2093 Q98228738-8D0CA360-2BB7-4B71-8F15-DE6E9A03116C @default.
- Q98228738 P2093 Q98228738-A1FC9352-4AD0-4BDA-86F9-696AEE43761E @default.
- Q98228738 P2093 Q98228738-CDF193C2-92D8-44CF-858A-64C875D607FE @default.
- Q98228738 P2093 Q98228738-CF0E685B-FA02-4AAA-BCAB-E3BEFB1D82E2 @default.
- Q98228738 P2093 Q98228738-D80D5AA8-2B76-4D91-AB25-382FBF6A55FB @default.
- Q98228738 P2093 Q98228738-E34BCE4D-B581-4AC5-A372-0CC0B4C9F5C5 @default.
- Q98228738 P2093 Q98228738-E71B7A8D-E711-4B06-8ACE-698C5A13462C @default.
- Q98228738 P2093 Q98228738-EAC3804D-ECED-4895-997B-144A339BB3DD @default.
- Q98228738 P2093 Q98228738-F901C4F0-F6EF-4064-8AA3-139519611C36 @default.
- Q98228738 P2093 Q98228738-FA24D8A5-3C30-4121-8873-D51E01DBE719 @default.
- Q98228738 P2093 Q98228738-FB3316C6-7C96-4101-98BD-5EACFB42587B @default.
- Q98228738 P304 Q98228738-CDB82FCB-3C0F-4016-AC5D-1EDED1A9C4A9 @default.
- Q98228738 P31 Q98228738-0DE51634-89C4-4617-82B1-BD085A091FE8 @default.
- Q98228738 P356 Q98228738-78340680-7970-4422-92F5-4C060D06BC09 @default.
- Q98228738 P50 Q98228738-418AE753-639D-440F-869F-695BA24E7EDA @default.
- Q98228738 P577 Q98228738-61C13303-68D6-48AF-94BA-AC5F8EAE5D6A @default.
- Q98228738 P698 Q98228738-DA047912-1540-4822-BA04-0EAB529039EB @default.
- Q98228738 P921 Q98228738-175B7DBF-8E2E-4BEC-A70A-4496E783A062 @default.
- Q98228738 P356 0284186X.2020.1781249 @default.
- Q98228738 P698 32762415 @default.
- Q98228738 P1433 Q326164 @default.
- Q98228738 P1476 "Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab" @default.
- Q98228738 P2093 "Alessandro De Toma" @default.
- Q98228738 P2093 "Alessio Gili" @default.
- Q98228738 P2093 "Alex Friedlaender" @default.
- Q98228738 P2093 "Ana Collazo-Lorduy" @default.
- Q98228738 P2093 "Andrea Camerini" @default.
- Q98228738 P2093 "Antonio Calles" @default.
- Q98228738 P2093 "Athina Christopoulou" @default.
- Q98228738 P2093 "Beatriz Jimenez" @default.
- Q98228738 P2093 "Diego Signorelli" @default.
- Q98228738 P2093 "Domenico Galetta" @default.
- Q98228738 P2093 "Fausto Roila" @default.
- Q98228738 P2093 "Giannis Mountzios" @default.
- Q98228738 P2093 "Giulio Metro" @default.
- Q98228738 P2093 "Giuseppe Banna" @default.
- Q98228738 P2093 "Giuseppe Lo Russo" @default.
- Q98228738 P2093 "Helena Linardou" @default.
- Q98228738 P2093 "Marco Banini" @default.
- Q98228738 P2093 "Marina C Garassino" @default.
- Q98228738 P2093 "Panagiota Economopoulou" @default.
- Q98228738 P2093 "Panagiotis Baxevanos" @default.
- Q98228738 P2093 "Paris Kosmidis" @default.
- Q98228738 P304 "1-6" @default.
- Q98228738 P31 Q13442814 @default.
- Q98228738 P356 "10.1080/0284186X.2020.1781249" @default.
- Q98228738 P50 Q91554256 @default.
- Q98228738 P577 "2020-06-17T00:00:00Z" @default.
- Q98228738 P698 "32762415" @default.
- Q98228738 P921 Q13896859 @default.